EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

• click to rate

  Posted by Two Blokes May 23 - Filed in Stock - 4 views
  
  Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.